MedTrace Logo

KW-3357 Study in Patients With Early Onset Severe Preeclampsia

NCT04182373 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 181

Last updated 2023-11-15

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of intravenous KW-3357 in patients with early-onset severe preeclampsia by comparing the prolongation days of pregnancy with that of placebo.

Conditions

Interventions

DRUG

Antithrombin gamma

Intravenous infusion, once a day, 7 days

DRUG

physiological saline

Intravenous infusion, once a day, 7 days

Sponsors & Collaborators

  • Japan Blood Products Organization

    collaborator INDUSTRY

  • Kyowa Kirin Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-19
Primary Completion
2023-05-17
Completion
2023-06-16

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04182373 on ClinicalTrials.gov